INTRODUCTION
Metronidazole, 2-(2-methyl-5-nitro-1H-imidazole-1-ilo) ethanol, is a chemotherapeutic agent showing activity both against protozoa, such as Balantidium coli, Blastocystis hominis, Entamoeba histolytica, (Giardia lamblia), Trichomonas vaginalis, Diantamoeba fragilis, Enterocytozoon bieneusi, Septata intestinalis and Encephalitozoon helleri, and also against Gram-positive bacteria, e.g. from the genera Eudragit FS 30D as a potential polymer for use in the technology of preparing matrix tablets contain metronidazole -an experimental and mathematical modeling study Current Issues in Pharmacy and Medical Sciences a sustained-release drug allows for minimizing the adverse effects of metronidazole action (which strictly correlate with a rapid growth of drug concentration in the serum), and increases the comfort of patient's treatment as a result of decreasing the frequency of drug dosage. Due to the biopharmaceutic properties of metronidazole, such as belonging to class I of BCS and the average biological half life time (t 0,5 ) being 8h, it is an ideal model substance for the development of formulations with a sustained-release profile [9] . One of the methods which allow modifying the active substance release is the fabrication of matrixes. For this purpose, ethylcelluloses are commonly used. This is both due to their ability to swell and to their susceptibility to compression, which often allows the construction of sustained-release matrixes by direct tabletting. Of this group of polymers, methylcellulose (MC), hydroxypropylmethylcellulose (HPMC), hydroxypropylcellulose (HPC) and carboxymethylcellulose sodium (CMCNa) are commonly included in the composition of matrix tablets.
For many model substances, the relationship has been examined between the release rate from matrix tablets and the viscosity and size of HPMC particles, the percentage in formulations and the production method of this form [2, 23, 24] . In tablets containing 400 mg of metronidazole, sustained release over 8h was obtained by including in the composition, HPMC in quantities between 10% -30% (w/w) of the active substance. Herein, the matrix was obtained by compressing the granulated material obtained by wet granulation [2] .
In our work, of the synthetic polymers, we examined the usefulness of polyvinylpyrrolidone (Povidone), polyvinyl acetate (Kollidon SR) and polyacrylate (Carbopol 71G) in modifying the metronidazole release from matrix tablets. The mentioned polymers were included in the composition in a ratio of 1:1 (w/w) to the active substance. The tablets were fabricated by way of the direct compression method, and sustained metronidazole release was achieved in all the freshly made formulations. The dissolution test was also conducted during an artificial aging, at 40°C ± 2°C and 75% ± 5% RH for 4 weeks. Based on the obtained results, we eliminated the possibility of employing Carbopol 71G as an excipient in designing such matrixes [20] .
Our work emphasized the advantages of using lipids in sustained release systems. Matrixes based on these excipients are obtainable with a high degree of repetitiveness and at a relatively small expense. Moreover, they are characterized by their positive chemical compatibility with other substances [13, 16] .
In our study, matrix tablets with metronidazole were obtained by including in the composition, Carnauba wax, Beeswax, Stearic acid, Cutina HR, Precirol® ATO 5 and Compritol® ATO 888. The ratio of the active substance to lipophilic excipients was 2:1 (w/w). All tablets were characterized by a sustained time of release, in accordance with first-order kinetics [14] . (Meth)acrylate copolymers, produced by Evonik Röhm (Germany) are commonly used in the technology of matrix tablet production under the name 'Eudragit'. To achieve the sustained release of the active substance, both copolymers with the nature of polycations (RS or RL) and their mixture with polyanions (L or S) are incorporated in the studied substance, as well as the Eudragits which do not have groups with the ability to ionize (NM or NE) [4] .
The aim of our study was to examine the usefulness of the pH-dependent copolymer -Eudragit FS -in the technology of manufacturing modified-release metronidazole matrix tablets.
As opposed to other polyanionic Eudragits (L and S), this copolymer is characterized by possessing a smaller proportion of free carboxyl groups (metacrylic acid monomers), which affects its solubility. Eudragit FS 30D is used to coat pellets to obtain a colon release of active substance by way of its dissolution at pH = 6.8 [6, 12] . As the trade form of Eudragit FS is a 30% water dispersive, it was assumed that the copolymer will be employed as a binder in the process of metronidazole wet granulation, and, subsequently, the resulting intermediate product will then be tabletted.
Our study was set-up to meet several objectives. One objective of this study was to estimate the effect on the active substance release rate of surface-active substances and the included polycationic Eudragits.
Moreover, the objective of our undertaken numerical analysis was to estimate the release kinetics of metronidazole from the prepared formulations throughout the stages of the experiment. In so doing, standard numerical methods, widely described in current literature, were employed [25] . Another objective was to determine the mechanism of substance release from tablets at the initial stage of the process. Two known approaches were used. These were in accordance with the Ritger-Peppas theory and the Peppas-Sahlin theory [17, 19] .
MATERIALS AND METHODS
The active substance utilized in our work was Metronidazole (Polpharma, Polska). As polymers for modifying its release, we used copolymers of metacrylic and acrylic acid esters in the form of trade water dispersions. These were: Eudragit RS 30D, Eudragit RL 30D and Eudragit FS 30D (Evonik, Germany) . Moreover, we employed as surface-active substances: polysorbate 80 (POCH, Poland) and sodium lauryl sulfate (Caleo, Germany). Magnesium stearate (POCH, Poland) was availed as a lubricant.
Granulation: Metronidazole was first weighed and sieved through a 0.08 mm screen. The active substance, in the course of mixing with a planetary-motion paddle, was then wetted with water dispersions of Eudragit FS 30D, Eudragit RS 30D and Eudragit RL 30D. Depending on the formulation, polysorbate 80 or sodium lauryl sulfate dissolved in a small amount of water was additionally included in the wetted mass of powders. The whole was mixed thoroughly for 20 minutes and transferred to a oscillating granulator (Erweka). Granulated material was formed by passing the wetted mass of powders through a 1.25 mm screen and dried at 40°C to reach 4% of humidity. The obtained intermediate product for tabletting was homogenized through a set of screens with a diameter from 0.315 mm to 1.25 mm. Compositions of all formulations are listed in Table 1 .
Matrix tablets: Magnesium stearate (0.5% w/w) was added to the fraction of granulated material left on the 0.315 mm and 0.710 mm screens, and mixed for 3 minutes. The tablet base was compressed using a single punch tablet press Korsch EK-0. Matrix and punches with a diameter of 10 mm were used for tabletting. The declared content of metronidazole in all formulations was 500 mg.
Physicochemical evaluation of prepared tablets: As part of the qualitative assessment, the mass homogeneity was examined for 20 randomly selected units. Deviation from the declared content of active substance was verified based on the spectrophotometric analysis of metronidazole from 10 randomly selected tablets from all developed formulations. In order to do so, the sample tablets were individually powdered, and three analytical samples were weighed from each, on the analytical balance, Sartorius Expert (Germany), to an accuracy of 0.0001 g. Each analytical sample was subsequently transferred to a measuring flask with a volume of 25 mL and supplemented with 0.1 N hydrochloric acid. It was then shaken for 10 minutes and filtered through Filtrak 380. From the filtrate, 1 mL of the solution was collected with an automatic measuring pipette, and transformed to a measuring flask with a volume of 10 mL. This was supplemented with 0.1 N hydrochloric acid. The solution was subjected to spectrophotometric analysis at the analytic wavelength of 277 nm.
Friabilility (F) was determined as a percentage loss in weight. For this purpose, about 6.5 g of tablets were weighed and then revolved (25 r/min) in an Erweka TAR 200 friabilator for 4 minutes and weighed once more.
Determination of tablet metronidazole content -validation of the method: The metronidazole content in the prepared tablets and the amount of released active substance in the dissolution test study were determined using the UV spectrophotometric method. The spectrophotometer Jasco V-530 was used for this analysis. The method of quantitative metronidazole determination was validated in accordance with the ICH guidelines [7] .
A 6-point calibration curve was constructed, based on the absorbance determination of metronidazole model solutions with a concentration of 5.5 µg/mL -19.3 µg/mL in 0.1 N hydrochloric acid, at the maximum of absorption 277 nm. A second model curve was also determined, based on the analysis of suspensions with a concentration of 3.6 µg/mL -13.5 µg/mL in pH 6.8 phosphate buffer, at the analytical wavelength 320 nm.
The accuracy of metronidazole determination in the fabricated matrix tablets was evaluated by a spectrophotometric analysis of three model formulations which contained, respectively, 85%, 100% and 115% of the declared content of the active substance, as well as the excipients included in the granulate materials. From each powdered formulation, three identical analytical samples were prepared for spectrophotometric analysis, in accordance with the procedure developed for determining the active substance content in prepared matrix tablets. The percentage of metronidazole recovery, which was calculated from the formula, was adopted as the measure of the method accuracy:
The precision of metronidazole determination was calculated by standard deviation (RSD), which was based on an analysis of active substance content in model formulations (n = 3). The degree of method selectiveness demonstrated was based on the spectrophotometric analysis of solutions of excipients which were included in tablet compositions, in 0.1 N hydrochloric acid and pH 6.8 phosphate buffer at the analytical wavelengths: 277 nm and 320 nm.
Dissolution appraisal: An assessment of the metronidazole dissolution from the developed formulations of tablets was performed using the apparatus 1, according to USP 32 [22] . In this work, 0.1 N hydrochloric acid pH 1.2 and pH 6.8 phosphate buffer were used as acceptor fluids. The temperature of the resulting fluids was kept at 37°C ± 0.5°C, with the mixing rate amounting to 75 rpm. An evaluation of metronidazole release rate was performed in the apparatus ERWEKA DT 600HH (Germany), where the tested tablet was placed in each of six baskets. The volume of acceptor fluids was 750 mL, which provided sink conditions. After 2h from the start of the study, the acceptor fluid was changed from pH 1.2, to pH 6.8. At time points 1, 2, 3, 4, 6, 8 and 10 h, samples with a volume of 2 mL were collected. The sample volumes were then immediately replaced with the appropriate acceptor fluid. These samples were filtered (0.45 µm), suitably diluted with 0.1 N hydrochloric acid or phosphate buffer and subjected to spectrophotometric analysis for metronidazole content at the analytical wavelengths: 277 nm and 320 nm.
Comparison of the dissolution curves: A mathematical comparison of metronidazole release profiles was performed by calculating the similarity coefficient f2, according to Eq. (2), proposed by Moore and Flanner [10] , and implemented by FDA CDER. Calculations were made using the program DDSolver [25] . F1  F2  F3  F4  F5  F6  F7  F8  F9  F10  F11  F12   Metronidazole  100  100  100  100  100  100  100  100  100  100  100  100   Eudragit FS*  4  2  2  2  2  3  3  3  6  6  3  3 Eudragit RS* -
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The f2 value between 50 and 100 suggests that the dissolution profiles are similar. The f2 value of 100 suggests that the test and reference release profiles are identical.
Solubility of metronidazole:
The examination of metronidazole solubility in 0.1 N hydrochloric acid and pH 6.8 phosphate buffer was conducted in accordance with previously established guidelines [15] . For each of these solvents, three analytical samples of the substance were prepared. Metronidazole content in the solution was determined by way of the UV spectrophotometry method.
Examination of release kinetics:
To analyze the mechanism and kinetics of metronidazole release from the fabricated matrix tablets into the acceptor fluid, several different mathematic models were employed, which were matched to the experimental data. We use: zero-order release kinetics, first-order release kinetics, second-order release kinetics, the Weibull model, the Ritger-Peppas model and the PeppasSahlin model, all of which are defined by the equations: The zero order rate, eq. (3), describes systems wherein the drug release is independent of its concentration. The first-order release kinetics, eq. (4), and the second-order release kinetics, eq. (5), describe the release from systems which are concentration dependent. The obtained empirical data were, as well, analyzed for the possibility of using the Weibull model, eq. (6), for describing metronidazole release kinetics. In the Weibull model, parameter B determines the phenomenon character [18] . If parameter B > 1, the drug release rate is not a monotonically decreasing function of time. For time periods smaller than some t max , the function increases monotonically. At the moment t max , this function has a maximum, and then for all the times greater than tmax, the function decreases monotonically to zero. In the situation wherein 0 < B ≤ 1, the drug release rate decreases for all the times t > 0. In this case there is no maximum velocity.
To establish the tablet's drug substance release mechanism, the Ritger-Peppas model was employed [19] . This model functions well for time ranges where the amount of the released substance does not exceed 60% [17] . It is defined by equation (7) . In an ideal situation, for tablets of spherical form and with a diffuse mechanism of drug release, the theory predicts that n should be equal to n = 0.43. Case II transport is present when the coefficient n = 0.85. If the coefficient is within the range 0.43 < n < 0.85, superposition of both processes occurs. In contrast, when n > 0.85, a super case II type of release is seen [3, 19] .
Regarding the Peppas-Sahlin model, equation (8) , the first part describes diffusion, the second refers to Case II transport. The actual process is described by way of being a superposition of both processes. Numbers k1 and k2 describe the contributions of these two processes to the observed drug release [19] .
The adequacy of the employed models was tested by way of calculating three quantities: determination coefficient (R 2 ), residual sum of squares (SSR) and Akaike's information criterion (AIC) [3, 17] .
RESULTS AND DISCUSSION

Evaluation of prepared matrix tablets
In our study, matrix tablets with metronidazole were first produced by compressing agglomerates. The composition of all prepared formulations, expressed in the amount of excipients per 100 g metronidazole, was presented in Table 1 . UV spectrophotometry was subsequently used to quantitatively determine the model substance in matrix tablets. The analytic method developed was characterized by specificity, as excipients composing the tablets did not show absorbance at the analytical wavelengths of 277 nm and 320 nm. Of note: in this part of the study, we did not see that the degradation products of metronidazole that appear under the influence of light had any influence on the results of quantitative spectrophotometric analysis in UV [5] .
Our work revealed a linear relationship between the defined metronidazole concentration in model solutions and absorbance. For the calibration curve in 0.1 N hydrochloric acid, the regression equation took the form y = 0.0369x + 0.0136 (R 2 = 0.9996), whereas for the model curve determined by way of the phosphate buffer, y = 0.0528x + 0.0014 (R 2 = 0.9998). The accuracy of the analytical method was assessed through metronidazole recovery from the model matrix tablets. This recovery ranged from 100.61%, to 101.66%, at RSD < 1% for n = 3. In the adopted range of concentrations, the UV method for metronidazole determination was characterized by linearity, specificity, accuracy and precision.
As part of the qualitative assessment of the obtained drug form, the homogeneity of the tablets mass, its active substance content and its friability were examined. The maximal deviation from the average mass which was obtained in the developed formulations amounted to 3.5%. The obtained value was lower than the criterion of acceptance defined in USP 32 for tablets with mass above 250 mg [22] .
This indicated good flow properties with regard to the granulated material, which resulted in even filling of the matrix in the course of tabletting. The highest values of deviation from the declared content of the active substance was 3.24% ( Table 2 ). The friability (F) figure obtained for all tablets was less than 1%.
Dissolution studies
A dissolution test was carried out for six tablets randomly selected from each developed formulations. Although metronidazole solubility in water is 1.0 g/100 mL [21] , the analysis was also performed for acceptor fluids, owing to their pH. The fabricated tablets demonstrated a Metronidazole solubility in 0.1 N hydrochloric acid of 2.55 g/100mL, whereas in phosphate buffer, this figure was 0.97 g/mL. The obtained results confirmed that sink conditions were maintained at the assumed volume of acceptor fluids.
Release profiles from the developed tablets formulations were drawn on curves which presented the relationship between the amount of released metronidazole (Q%), in relation to the declared dose, and time (t) ( Fig. 1 and Fig. 2) . The similarity coefficients f2 for individual metronidazole release profiles were presented in Table 3 . The differences in metronidazole release rate which were obtained during the study, were connected with the composition of the matrixes.
Of the excipients, only Eudragit FS was included in the tablets composition in formulation F1 and F2. At the ratio of polymer to metronidazole amounting to 1 : 25 and 1 : 50 (w/w), respectively, a modified active substance release was achieved. In formulation F1, 71% was released after 10 h, whereas in formulation F2, 81% of the declared metronidazole dose was determined in the acceptor fluid after this time. The calculated similarity coefficient f2 was 63, which indicates that the obtained release profiles are similar.
Formulation F2 was subsequently modified by adding the surface-active substances: sodium lauryl sulfate and polysorbate 80. This resulted in an increase in the active substance release rate. After 10h of analysis, from 91% (F5) to 98% (F4) of the declared metronidazole dose was evidenced.
Our work also revealed that at the ratio of Eudragit FS to metronidazole of 1 : 50 (w/w), no considerable differences in release profiles were observed which would be determined by varying the amount of introduced sodium Fn  F1  F2  F3  F4  F5  F6  F7  F8  F9  F10  F11  F12   F1  100  63  30  29  41  58  35  66  56  44  65  40   F2  63  100  34  32  48  66  39  51  45  38  51  46   F3  30  34  100  80  49  37  63  27  25  21  26  51   F4  29  32  80  100  45  35  57  25  23  20  25  47   F5  41  48  49  45  100  53  58  35  32  28  35  84   F6  58  66  37  35  53  100  44  47  43  35  47  51   F7  35  39  63  57  58  44  100  31  28  24  30  62   F8  66  51  27  25  35  47  31  100  73  54  88  34   F9  56  45  25  23  32  43  28  73  100  62  73  32   F10  44  38  21  20  28  35  24  54  62  100  54  27   F11  65  51  26  25  35  47  30  88  73  54  100  34   F12  40  46  51  47  84  51  62  34  32  27 34 100 Current Issues in Pharmacy and Medical Sciences lauryl sulfate. In this part of the experiment, the value of coefficient f2 calculated for formulations F3 and F4 was 80. Indeed, only in the case of an increased percentage of Eudragit FS in formulations F6 and F7 was a relationship seen between the amount of sodium lauryl sulfate included within the composition and the metronidazole release rate. Of note: during the analysis of all profiles, we observed that the addition of polysorbate 80 speeds up the active substance release to a lesser extent than including sodium lauryl sulfate within the formulation.
In formulary versions F11 and F12, Eudragit FS 30D and the cationic copolymers: Eudragit RS 30D and Eudragit RL 30D, were additionally used to wet the mass of powders. The direct combining of two types of copolymer dispersions of opposite charges demonstrated an interaction at the stage of mixture preparation -where flocculation was observed. The decrease of active substance release in the phosphate buffer was also an effect of this incompatibility [8, 12] . To prevent flocculation, we suggest that such tablets incorporating these polymers together be prepared by combining them in a dry form with the active substance, and then subjecting the mixture to direct compression [11] .
In our study, the fabricated agglomerates were obtained by direct wetting of the metronidazole with Eudragit FS 30D dispersive, and then during further mixing, with Eudragit RS 30D or Eudragit RL 30D. Owing to the held greater hydrophilic character of Eudragit RL (as compared with Eudragit RS), in formulation F12, at each time point, a higher metronidazole concentration in the acceptor fluid was ascertained than in the case of formulation F11. At the end point of our study, 66% and 91% (F11 and F12) of the declared metronidazole dose was estimated within the acceptor fluid.
Based on an analysis of the f2 factors, it was found that similar release profiles were obtained by modifying the composition of manufactured tablets which are with the same amount of Eudragit FS, by way of incorporating Eudragit RL (F12) and sodium lauryl sulfate (F6 and F7). A similar pattern was observed in produced tablets incorporating Eudragit RS and polysorbate 80 (F11 and F8) . Confirmation of the earlier mentioned interaction between Eudragits RS/RL and Eudragit FS, which, in our study, brought about a decrease in the active substance release rate [11] , would require introducing an acceptor fluid of pH 7.4 to the study. This should result in the maximal ionization of the carboxyl groups of the anionic polymer and produce a similar effect on a polymer with the opposite charge.
In all of the versions of the matrix tablets we had fabricated, irrespective of the composition, a decrease in metronidazole release rate was observed after 2h of analysis. This phenomenon, we put forward, may have come about by it being affected by a lower solubility of the active substance in the pH 6.8 phosphate buffer, as well as by the amount of metronidazole released to 0.1 N hydrochloric acid, and thus a longer way of diffusion of the substance solution from the tablet having had occur.
As compared with the earlier studies regarding the technology of matrix tablet manufacture with metronidazole, where Carbopol, Kollidon SR and Povidon were included in the composition as substances modifying release [20] , in formulations based on Eudragits, it was possible to obtain a smaller ejection of the substance during the 2h of release in 0.1 N hydrochloric acid. Hence, owing to the different parameters utilized within the dissolution test for metronidazole tablets of matrixes consisting of HPMC [14] lipids [4] , it was impossible to compare the previously obtained release profiles, with the results obtained in our study.
Examination of the kinetics and mechanism of metronidazole release from matrix tablets
The numerical analysis of the obtained experimental data for the drug release kinetics from the studied formulations are presented in Tables 4-6 . Parameters SSR, AIC and R 2 , therein, demonstrate explicitly that the drug release from all the formulations we examined could not be described as a zero-order process. This is because, all the criteria describing the adequacy of the zero-order model in relation to the experimental data, are worse than the same parameters for other possibilities. Based on the results of our analyses, it was determined that the drug release description for some of formulations was that of a first-order process. These are formulations: F2-F5. What is more, a group of formulations revealed a drug release description that could be described as being a second-order process. These were formulations F1, F6, F8-F11.
The analysis of formulations F7 and F12 did not explicitly determine the order of metronidazole release kinetics. Thus, for formulations F7 and F12, we leave open the problem of estimating the kinetics order, hence, requiring further studies.
Further analysis included the effect of Eudragit FS on the order of drug release kinetics. Such work excluded formulations F7, F11 and F12. Formulation F7 was excluded because of the problem with determining the release kinetics order, whereas tablet formulations F11 and F12 also contained Eudragit RS and Eudragit RL. In ascertaining the effect of Eudragit FS on this issue, Spearman's correlations were calculated between the release kinetics order shown before and the mass of Eudragit FS incorporated. The result of such calculations is a Spearman's coefficient rs= 0.9129, which gives the p-value being below 0.002.
In our work, beyond generating an estimation of drug release kinetics for all the time points within the experiment, the Weibull model was used. The result of such calculations are presented in Table 5 . In so doing, the analysis of parameter B indicates that the release rate of the various formulations cannot have been at a maximum in each formulation. Hence, to determine the mechanism of drug release, Ritger-Peppas theory was then applied. This model works well only for the time periods when 60% of any formulation item is released. Therefore, this method was used only for formulations: F1, F2, F8-F11, as the other matrix tablets released more than 60% of the metronidazole in too short time, in relation to the frequency of collecting a sample for the analysis. The results of applying Ritger-Peppas theory are presented in Table 6 . Based on numerical calculations, it was found that the process of release is more likely based on diffusion to the outside environment (as in all formulations, n had a value below 0.43). An identical result was obtained using the Peppas-Sahlin theory. The results for this model are presented in Table 6 . As revealed in applying this theory, the value of parameter k 1 is definitely higher than k 2 , hence, in this model, diffusion is the dominant mechanism of drug release.
